Identity
- Trade Name
- Diazyme FDA UDI
- Generic Name
- Kappa/lambda light chain immunoglobulin IVD, control FDA UDI
- Model / Reference
- 08896577190 FDA UDI
Identifiers
- Primary DI / UDI-DI
- 00817089023024 FDA UDI
- GMDN Term
- Kappa/lambda light chain immunoglobulin IVD, control FDA UDI
Classification
- Commercial Distribution
- In Commercial Distribution FDA UDI
Clinical & Handling
Sterile
No
FDA UDI
Single Use
No
FDA UDI
Implantable
No
FDA UDI
Contains Latex
No
FDA UDI
Prescription Use
No
FDA UDI
Over-the-Counter
No
FDA UDI
Convenience Kit
Yes
FDA UDI
Combination Product
No
FDA UDI
HCT/P
No
FDA UDI
Premarket Exempt
No
FDA UDI
Lot / Batch Number
Yes
FDA UDI
Serial Number
No
FDA UDI
Expiration Date
Yes
FDA UDI
Manufacturing Date
No
FDA UDI
Category: Kappa/lambda light chain immunoglobulin IVD, control
Diazyme by Diazyme Laboratories, Inc. — FDA UDI — listed in FDA GUDID — regulatory data on deviCERTS
Similar devices
Also classified as Kappa/lambda light chain immunoglobulin IVD, control.
- Kappa / FITC control slides — BIO SB, INC. · Class I
- Kappa Light Chains Control Slides — BIO SB, INC. · Class I
- Freelite® Human Kappa Free Control Pack For use on the Beckman Coulter IMMAGE™/ — The Binding Site Group · Class I
- Freelite® Panel Sample Set — The Binding Site Group · Class I
- Freelite® Human Lambda Free Control Pack for use on the Siemens BN™II — The Binding Site Group · Class I
- FLC Control Level 2 — Sebia, Inc. · Class II
- Lambda / FITC control slides — BIO SB, INC. · Class I
- Lambda Control Slides — BIO SB, INC. · Class I
Authorization Coverage (1 country)
Regulatory Authorizations
United States Pending data
FDA UDI
| Source | Region | Type | Cert / Approval No. | Class | Status |
|---|---|---|---|---|---|
| FDA UDI | United States | FDA UDI | Registered in GUDID | N/A | Pending data |
Is this your device? Claim it to add documentation and request validation.
Manufacturer
- Manufacturer
- Diazyme Laboratories, Inc.
Sources (1)
- FDA UDI e08061a3-9f9b-474a-b533-40ce3c36c885 32 fields · synced Jun 9, 2026